← All Silexion Therapeutics CORP filings

Silexion Therapeutics CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
SLXN
Silexion Therapeutics CORP
10-K/A: Silexion Therapeutics Files 10-K/A Amendment for FY 2025
Silexion Therapeutics Corp files an amendment to its 2025 annual report to correct internal control reporting dates.
NASDAQ
SLXN
Silexion Therapeutics CORP
10-K: Silexion Faces Going Concern Doubt Amidst R&D Push
Silexion Therapeutics Corp reports significant losses and substantial doubt about its ability to continue as a going concern, despite advancing its lead oncology candidate, SIL204, towards Phase 2/3 clinical trials.
NASDAQ
SLXN
Silexion Therapeutics CORP
10-K: Silexion Therapeutics Corp Details Share Structure and Warrant Terms in 10-K Filing
Silexion Therapeutics Corp outlines its share capital, warrant details, and corporate governance in its latest 10-K filing, highlighting key aspects of its securities registered under the Exchange Act.